company

UbiQ was founded in 2010 by the late professor Huib Ovaa, Farid El Oualid and Alfred Nijkerk as a spin-out of the Netherlands Cancer Institute (NKI) in Amsterdam, The Netherlands. Currently, UbiQ is independent of the NKI.

UbiQ’s own offices and laboratories are located at the Amsterdam Science Park in the Netherlands.

UbiQ reagents are sold worldwide directly from Amsterdam to biotech, pharma companies and academic research labs. Our standard shipping method is FedEx – International priority (incoterms: ex works).

During the period 2012 – 2018, UbiQ also lead some internal drug discovery programs (now abandoned): 

• UbiQ developed specific HTS assay reagents and conducted DUB-inhibitor screening programs for internal development.
  
  
• UbiQ pursued drug discovery programs on ubiquitin(-like) cascade inhibitors based on UbiQ’s Triple E platform. UbiQ developed this platform, published in Nature Chemical Biology (2016), which exploits a reacting group that specifically traps the E1, E2 and E3 ubiquitylating enzymes. By adding this ‘hook’ onto ubiquitin itself or onto a small molecule, it had become possible to monitor and/or block the activity of dozens of enzymes involved in protein ubiquitylation specifically. Our first program based on our Triple E technology was conducted in SumiQ Therapeutics, which developed mechanism-based covalent SUMOylation inhibitors, targeting non-oncogene SUMO addicted Myc, Notch1 or mutant KRAS driven cancers.